What Happens When We Sunburn


July 09, 2012  |  

Researchers describe inflammatory mechanism for first time

The biological mechanism of sunburn – the reddish, painful, protective immune response from ultraviolet (UV) radiation – is a consequence of RNA damage to skin cells, report researchers at the University of California, San Diego School of Medicine and elsewhere in the July 8, 2012 Advance Online Publication of Nature Medicine.

The findings open the way to perhaps eventually blocking the inflammatory process, the scientists said, and have implications for a range of medical conditions and treatments.


A photomicrograph of superficial keratinocytes or skin cells. Image courtesy of Thomas Deerinck, National Center for Microscopy and Imaging Research, UC
San Diego.
“For example, diseases like psoriasis are treated by UV light, but a big side effect is that this treatment increases the risk of skin cancer,” said principal investigator Richard L. Gallo, MD, PhD, professor of medicine at UC San Diego School of Medicine and Veterans Affairs San Diego Healthcare System. “Our discovery suggests a way to get the beneficial effects of UV therapy without actually exposing our patients to the harmful UV light. Also, some people have excess sensitivity to UV light, patients with lupus, for example. We are exploring if we can help them by blocking the pathway we discovered.”


Using both human skin cells and a mouse model, Gallo, first author Jamie J. Bernard, a post-doctoral researcher, and colleagues found that UVB radiation fractures and tangles elements of non-coding micro-RNA – a special type of RNA inside the cell that does not directly make proteins. Irradiated cells release this altered RNA, provoking healthy, neighboring cells to start a process that results in an inflammatory response intended to remove sun-damaged cells.

We see and feel the process as sunburn.

“The inflammatory response is important to start the process of healing after cell death,” said Gallo. “We also believe the inflammatory process may clean up cells with genetic damage before they can become cancer. Of course, this process is imperfect and with more UV exposure, there is more chance of cells becoming cancerous.”

Gallo said it’s still not known how gender, skin pigmentation and individual genetics may affect the mechanism of sunburn. “Genetics is closely linked to the ability to defend against UV damage and develop skin cancers,” he said. “We know in our mouse genetic models that specific genes will change how the mice get sunburn. Humans have similar genes, but it is not known if people have mutations in these genes that affect their sun response.”

Jamie J. Bernard is currently at the Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University. Other co-authors are Christopher Cowing-Zitron, Teruakai Nakatsuji, Beda Muehleisen, Jun Muto, Andrew W. Borkowski and Benjamin D. Yu, Division of Dermatology, UC San Diego; Laisel Martinez, Miami Veterans Affairs Medical Center; and Eric L. Greidinger, Miami Veterans Affairs Medical Center and Division of Rheumatology, University of Miami Miller School of Medicine.

Funding for this research came, in part, from National Institutes of Health grants R01-AR052728, R01-A1052453 and R01-A10833358, a Veteran Affairs Merit Award, National Institute of Environmental Health Sciences Training Grant ES007148 and NIEHS Center Grant ES005022, Department of Veterans Affairs, NIH AR48805 and the Lupus Research Institute.

# # #

Media Contact: Scott LaFee, 619-543-6163, slafee@ucsd.edu

Media Contact

Share This Article

Related News

New technique can reveal previously undetectable bacteria in places where they aren’t wanted — such as a spacecraft assembly facility, a neonatal intensive care unit and an abalone rearing center.
Each year, at precisely the same moment — 12 p.m. on the East coast, 9 a.m. on the West — thousands of graduating medical school students across the country simultaneously tear open an envelope. The s ...
Researchers at University of California San Diego School of Medicine, in collaboration with local biotechnology company Oncternal Therapeutics, have launched a phase Ib/II clinical trial to evaluate t ...
In clinical trial, treatment significantly reduced liver fat in NAFLD and NASH patients, offering possible new treatment for conditions that currently lack medical remedies.

Follow Us